Type Public Products Pharmaceutics Founded 1995 | Traded as NASDAQ: RMTI Website www.rockwellmed.com | |
 | ||
Industry Pharmaceutical Industry Stock price RMTI (NASDAQ) US$ 6.05 -0.01 (-0.17%)20 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Wixom, Michigan, United States | ||
Rockwell Medical Inc. is an international pharmaceutical company focusing on the development and commercialization ancillary hemodialysis products, for treatment against diseases such as end-stage renal disease, iron deficiency, chronic kidney disease (CKD), etc. The company's products mainly sell to the United States, Asia, Europe and Latin America. The company was formerly named Rockwell Medical Technologies, Inc., and is now a publicly traded company on NASDAQ under the symbol "RMTI".
Contents
This company performed top during 2013, among biopharmaceutical companies in the US and has two largest dialysis centers in the US, DaVita (DVA) and Fresenius (FMS), as the buyer of its products.
13 55919 richard yocum v rockwell medical technologies
Treatment
One of the main treatment that the company develops is for iron supplementation, a key element in the formation of new red blood cells. The product is called soluble ferric pyrophosphate (SFP), and its therapy was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis, since the process accounts for treatment in around 90 percent of anemia patients. The clinical experiment for this treatment is under Phase III during 2011.
In February 2014, the Company completed its large-scale, long-term safety study for iron maintenance drug Triferic.
Acquisition
In December 2011, Rockwell Medical Inc. acquired an abbreviated new drug application (ANDA), which is used for calcitriol, an intravenous Vitamin D analogue, in a gene-related version.